ANDA 75318, held by Chartwell Rx. Ticlopidine Hydrochloride.
As of Nov 16, 2026, ANDA 75318 (Ticlopidine Hydrochloride), held by Chartwell Rx, was first approved by FDA on Aug 20, 1999, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 20, 1999 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ticlopidine Hydrochloride250MG ยท tablet;oral | Ticlopidine Hydrochloride | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters